Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBCAR269B is an investigational **allogeneic BCMA-directed CAR-T cell therapy** being developed by Precision BioSciences for relapsed or refractory multiple myeloma. It is a next-generation successor to PBCAR269A and is engineered using the company's ARCUS genome editing platform to target **B-cell maturation antigen** on malignant plasma cells while incorporating **stealth cell** features intended to reduce host immune recognition and improve persistence of donor-derived CAR-T cells. The program was described as being in IND-enabling development with plans for IND filing in early 2022, indicating a preclinical-stage off-the-shelf cell therapy designed for antimyeloma immunotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PBCAR269B.